COVID-19 is caused by novel coronavirus(2019-nCoV),which has the characteristics of strong infectivity,rapid onset and rapid spread.It is popular in China and other parts of the world,and there are no special drugs at...COVID-19 is caused by novel coronavirus(2019-nCoV),which has the characteristics of strong infectivity,rapid onset and rapid spread.It is popular in China and other parts of the world,and there are no special drugs at present.This disease belongs to the category of plague in traditional Chinese medicine.Combined with the theory of triple energizer transmission in Yang Lishan's"Identification of Warm Disease",the confirmed case in our hospital was analyzed,and it was found that pathogenic qi entered from nose and mouth,injected into middle energizer,and then distributed in upper and lower energizer.The pathogenic qi is mainly diffused in the middle and upper energizer.Modified Maxing Ganshi decoction has a good effect.展开更多
Background:The COVID-19 has a huge negative impact on people’s health.Traditional Chinese Medicine(TCM)has a good effect on viral pneumonia.It is of great practical significance to study its pharmacology.Methods:The ...Background:The COVID-19 has a huge negative impact on people’s health.Traditional Chinese Medicine(TCM)has a good effect on viral pneumonia.It is of great practical significance to study its pharmacology.Methods:The ingredients and targets of each herb in Maxing Shigan Decoction which obtained from Traditional Chinese Medicine Systems Pharmacology(TCMSP)database,and the related targets of COVID-19 were screened by GeneCards database based on the network pharmacology.Venn was used to analyze the intersection target between active ingredients and diseases.Cytoscape software was used to construct an active ingredient-disease target network.The protein-protein interaction network was constructed by STRING database and Cytohubba was used to screen out the key targets.Gene Ontology(GO)functional enrichment analysis and KEGG pathway analysis were performed by DAVID database.Results:In this study,a total of 134 active ingredients and 229 related targets,198 targets of COVID-19 and 48 common targets of drug-disease were chosen.Enrichment items and pathways were obtained through GO and KEGG pathway analysis.The predicted active ingredients were quercetin,kaempferol,luteolin,naringenin,glycyrol,and the key targets involved IL6,MAPK3,MAPK8,CASP3,IL10,etc.The results showed that the active ingredients of Maxing Shigan Decoction acted on multiple targets which played roles in the treatment of COVID-19 by regulating inflammation,immune system and other pathways.Conclusions:The main contribution of this paper is to use data to mine the principles of the treatment of COVID-19 from the pharmacology of these prescriptions,and the results can be provided theoretical reference for medical workers.展开更多
Influenza is an acute viral respiratory infection that has caused high morbidity and mortality worldwide.Influenza A virus(IAV)has been found to activate multiple programmed cell death pathways,including ferroptosis.F...Influenza is an acute viral respiratory infection that has caused high morbidity and mortality worldwide.Influenza A virus(IAV)has been found to activate multiple programmed cell death pathways,including ferroptosis.Ferroptosis is a novel form of programmed cell death in which the accumulation of intracellular iron promotes lipid peroxidation,leading to cell death.However,little is known about how influenza viruses induce ferroptosis in the host cells.In this study,based on network pharmacology,we predicted the mechanism of action of Maxing Shigan decoction(MXSGD)in IAV-induced ferroptosis,and found that this process was related to biological processes,cellular components,molecular function and multiple signaling pathways,where the hypoxia inducible factor-1(HIF-1)signaling pathway plays a significant role.Subsequently,we constructed the mouse lung epithelial(MLE-12)cell model by IAV-infected in vitro cell experiments,and revealed that IAV infection induced cellular ferroptosis that was characterized by mitochondrial damage,increased reactive oxygen species(ROS)release,increased total iron and iron ion contents,decreased expression of ferroptosis marker gene recombinant glutathione peroxidase 4(GPX4),increased expression of acyl-CoA synthetase long chain family member 4(ACSL4),and enhanced activation of hypoxia inducible factor-1α(HIF-1α),induced nitric oxide synthase(iNOS)and vascular endothelial growth factor(VEGF)in the HIF-1 signaling pathway.Treatment with MXSGD effectively reduced intracellular viral load,while reducing ROS,total iron and ferrous ion contents,repairing mitochondrial results and inhibiting the expression of cellular ferroptosis and the HIF-1 signaling pathway.Finally,based on animal experiments,it was found that MXSGD effectively alleviated pulmonary congestion,edema and inflammation in IAV-infected mice,and inhibited the expression of ferroptosis-related protein and the HIF-1 signaling pathway in lung tissues.展开更多
目的:通过Meta分析清金化痰汤合麻杏石甘汤治疗慢性阻塞性肺疾病(简称慢阻肺)的疗效及安全性。方法:利用PubMed数据库、中国知网等数据库,检索自建库至2022年10月有关清金化痰汤合麻杏石甘汤治疗慢阻肺的临床随机对照试验。依据Cochran...目的:通过Meta分析清金化痰汤合麻杏石甘汤治疗慢性阻塞性肺疾病(简称慢阻肺)的疗效及安全性。方法:利用PubMed数据库、中国知网等数据库,检索自建库至2022年10月有关清金化痰汤合麻杏石甘汤治疗慢阻肺的临床随机对照试验。依据Cochrane风险偏倚评估工具对符合纳入标准的文献进行质量评估,并利用RevMan 5.4软件进行Meta分析。结果:最终有6项临床研究符合纳入标准,总计443例患者(试验组221例,对照组222例)。清金化痰汤合麻杏石甘汤(试验组)显著提高总有效率[OR=6.64,95%CI(2.45,17.98),P<0.00001];改善咳嗽[MD=-1.09,95%CI(-1.21,-0.97),P<0.00001]、喘息[MD=-1.18,95%CI(-1.31,-1.06),P<0.00001]、哮鸣音症状[MD=-1.05,95%CI(-1.13,-0.97),P<0.00001];显著提高显著提高第1秒用力呼气量(Forced Expiratory Volume in First Second,FEV_(1))[MD=0.44,95%CI(0.34,0.53),P<0.00001]、第1秒用力呼气量占预计值的百分比(FEV_(1)%)[MD=5.48,95%CI(3.32,7.64),P<0.00001];且并未增加不良反应的发生[RR=0.79,95%CI(0.43,1.45),P=0.45]。结论:清金化痰汤合麻杏石甘汤可提高治疗慢阻肺的临床疗效,改善临床症状,且安全性高。展开更多
基金The Science and Technology Program of Guangdong,China(nos.SDZX2020024SDZX2020055).+6 种基金Project of Chinese Medicine Administration of Guangdong Province,China(nos.2020ZYYJ182020139220201388Guangdong Traditional Chinese Medicine[2019]No.1)Science and Technology Program of Yangjiang,China(nos.201839201950)。
文摘COVID-19 is caused by novel coronavirus(2019-nCoV),which has the characteristics of strong infectivity,rapid onset and rapid spread.It is popular in China and other parts of the world,and there are no special drugs at present.This disease belongs to the category of plague in traditional Chinese medicine.Combined with the theory of triple energizer transmission in Yang Lishan's"Identification of Warm Disease",the confirmed case in our hospital was analyzed,and it was found that pathogenic qi entered from nose and mouth,injected into middle energizer,and then distributed in upper and lower energizer.The pathogenic qi is mainly diffused in the middle and upper energizer.Modified Maxing Ganshi decoction has a good effect.
基金the National Natural Science Foundation of China(Nos.62072157 and 61802116)the Natural Science Foundation of Henan province(202300410102)+1 种基金the Doctoral program of Henan Institute of Technology(KQ2002)the Science and Technology Research Key Project of Henan Province(No.192102210113).
文摘Background:The COVID-19 has a huge negative impact on people’s health.Traditional Chinese Medicine(TCM)has a good effect on viral pneumonia.It is of great practical significance to study its pharmacology.Methods:The ingredients and targets of each herb in Maxing Shigan Decoction which obtained from Traditional Chinese Medicine Systems Pharmacology(TCMSP)database,and the related targets of COVID-19 were screened by GeneCards database based on the network pharmacology.Venn was used to analyze the intersection target between active ingredients and diseases.Cytoscape software was used to construct an active ingredient-disease target network.The protein-protein interaction network was constructed by STRING database and Cytohubba was used to screen out the key targets.Gene Ontology(GO)functional enrichment analysis and KEGG pathway analysis were performed by DAVID database.Results:In this study,a total of 134 active ingredients and 229 related targets,198 targets of COVID-19 and 48 common targets of drug-disease were chosen.Enrichment items and pathways were obtained through GO and KEGG pathway analysis.The predicted active ingredients were quercetin,kaempferol,luteolin,naringenin,glycyrol,and the key targets involved IL6,MAPK3,MAPK8,CASP3,IL10,etc.The results showed that the active ingredients of Maxing Shigan Decoction acted on multiple targets which played roles in the treatment of COVID-19 by regulating inflammation,immune system and other pathways.Conclusions:The main contribution of this paper is to use data to mine the principles of the treatment of COVID-19 from the pharmacology of these prescriptions,and the results can be provided theoretical reference for medical workers.
基金supported by the National Natural Science Foundation of China(No.81973670)the Natural Science Foundation of Hunan Province(No.2020J5418)Hunan Provincial Open Fund of the Key Laboratory of the Pathogen Biology of Integrated Traditional Chinese and Western Medicine(No.2022-KFJJ02).
文摘Influenza is an acute viral respiratory infection that has caused high morbidity and mortality worldwide.Influenza A virus(IAV)has been found to activate multiple programmed cell death pathways,including ferroptosis.Ferroptosis is a novel form of programmed cell death in which the accumulation of intracellular iron promotes lipid peroxidation,leading to cell death.However,little is known about how influenza viruses induce ferroptosis in the host cells.In this study,based on network pharmacology,we predicted the mechanism of action of Maxing Shigan decoction(MXSGD)in IAV-induced ferroptosis,and found that this process was related to biological processes,cellular components,molecular function and multiple signaling pathways,where the hypoxia inducible factor-1(HIF-1)signaling pathway plays a significant role.Subsequently,we constructed the mouse lung epithelial(MLE-12)cell model by IAV-infected in vitro cell experiments,and revealed that IAV infection induced cellular ferroptosis that was characterized by mitochondrial damage,increased reactive oxygen species(ROS)release,increased total iron and iron ion contents,decreased expression of ferroptosis marker gene recombinant glutathione peroxidase 4(GPX4),increased expression of acyl-CoA synthetase long chain family member 4(ACSL4),and enhanced activation of hypoxia inducible factor-1α(HIF-1α),induced nitric oxide synthase(iNOS)and vascular endothelial growth factor(VEGF)in the HIF-1 signaling pathway.Treatment with MXSGD effectively reduced intracellular viral load,while reducing ROS,total iron and ferrous ion contents,repairing mitochondrial results and inhibiting the expression of cellular ferroptosis and the HIF-1 signaling pathway.Finally,based on animal experiments,it was found that MXSGD effectively alleviated pulmonary congestion,edema and inflammation in IAV-infected mice,and inhibited the expression of ferroptosis-related protein and the HIF-1 signaling pathway in lung tissues.
文摘目的:通过Meta分析清金化痰汤合麻杏石甘汤治疗慢性阻塞性肺疾病(简称慢阻肺)的疗效及安全性。方法:利用PubMed数据库、中国知网等数据库,检索自建库至2022年10月有关清金化痰汤合麻杏石甘汤治疗慢阻肺的临床随机对照试验。依据Cochrane风险偏倚评估工具对符合纳入标准的文献进行质量评估,并利用RevMan 5.4软件进行Meta分析。结果:最终有6项临床研究符合纳入标准,总计443例患者(试验组221例,对照组222例)。清金化痰汤合麻杏石甘汤(试验组)显著提高总有效率[OR=6.64,95%CI(2.45,17.98),P<0.00001];改善咳嗽[MD=-1.09,95%CI(-1.21,-0.97),P<0.00001]、喘息[MD=-1.18,95%CI(-1.31,-1.06),P<0.00001]、哮鸣音症状[MD=-1.05,95%CI(-1.13,-0.97),P<0.00001];显著提高显著提高第1秒用力呼气量(Forced Expiratory Volume in First Second,FEV_(1))[MD=0.44,95%CI(0.34,0.53),P<0.00001]、第1秒用力呼气量占预计值的百分比(FEV_(1)%)[MD=5.48,95%CI(3.32,7.64),P<0.00001];且并未增加不良反应的发生[RR=0.79,95%CI(0.43,1.45),P=0.45]。结论:清金化痰汤合麻杏石甘汤可提高治疗慢阻肺的临床疗效,改善临床症状,且安全性高。